Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

571 articles

Showing 1–2 of 2 articles · Keyword: Colorectal cancer Clear keyword

Cancer genomics & proteomics2026ResearchNon-viral Gene DeliveryDrug Delivery

1. FGFR4 Enhances Extracellular Vesicle-Associated Output and Promotes STAT1-Dependent LGALS3BP Enrichment in Colorectal Cancer

Kim Dh, Choi Jn, Hwang Je, Shim Hj, Bang Hj, Kim Hj, Et Al.

Fibroblast growth factor receptor 4 (FGFR4) contributes to colorectal cancer (CRC) progression, but its effects on extracellular vesicle (EV)-associated proteins remain unclear. In the present study, we examined FGFR4-associated changes in EV-enriched extracellular fractions and the role of STAT1 in LGALS3BP…

Read the article
Cytotechnology2026ResearchDrug Delivery

2. Chitosan nanoparticles functionalised with protocatechuic acid improve colon-targeted pazopanib delivery with multi-pathway therapeutic regulation and pharmacokinetic optimisation in colorectal cancer

Maheshwari T, Bhattacharya S

Poor pharmacokinetics, insufficient tumor-selective drug accumulation, and systemic toxicity are often the main obstacles to colorectal cancer (CRC) treatment. Here, protocatechuic acid-functionalized chitosan nanoparticles (PAZ-CS-PCA-NPs) were designed to enhance the pharmacological efficacy of pazopanib via…

Read the article
Articles | Brilliant Blue Biosciences